The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Open accessAbstract
Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effect of chemotherapeutic agents on MDSCs. Agents that inhibit MDSCs may be useful in the treatment of patients with various cancers. Experimental Design: We investigated the in vivo effects of docetaxel on immune function in 4T1-Neu mammary tumor-bearing mice to examine if a favorable immunomodulatory effect accompanies tumor suppression. Primary focus was on the differentiation status of MDSCs and their ability to modulate T-cell responses. Results: Docetaxel administration significantly inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC proportion in the spleen. The treatment also selectively increased CTL responses. Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA323-339 showed OT-II–specific CD4 activation and expansion in vitro. In characterizing the phenotype of MDSCs for M1 (CCR7) and M2 [mannose receptor (CD206)] markers, MDSCs from untreated tumor bearers were primarily MR+ with few CCR7+ cells. Docetaxel treatment polarized MDSCs toward an M1-like phenotype, resulting in 40% of MDSCs expressing CCR7 in vivo and in vitro, and macrophage differentiation markers such as MHC class II, CD11c, and CD86 were upregulated. Interestingly, docetaxel induced cell death selectively in MR+ MDSCs while sparing the M1-like phenotype. Finally, inhibition of signal transducer and activator of transcription 3 may in part be responsible for the observed results. Conclusions: These findings suggest potential clinical benefit for the addition of docetaxel to current immunotherapeutic protocols. Clin Cancer Res; 16(18); 4583–94. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although 5-fluorouracil, doxorubicin, gemcitabine, and docetaxel reduced circulating myeloid-derived suppressor cells (MDSCs) in mouse models [42–45]”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,258
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Cited by
Sorted by citations
Items 101–200 of 499
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 103
Myeloid‐derived suppressor cells as effectors of immune suppression in cancer
Pyzer, A. R., Cole, L., Rosenblatt, J. M., & Avigan, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30232 · Cited by 101
Zhao, Y., Zheng, Y., Zhu, Y., Li, H., Zhu, H., & Liu, T. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01526-2 · Cited by 100
Targeting tumor-associated macrophages to combat pancreatic cancer
Cui, R., Yue, W., Lattime, E. C., Stein, M. N., Xu, Q., & Tan, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9383 · Cited by 101
Sono/Photodynamic Nanomedicine‐Elicited Cancer Immunotherapy
Li, Y., Xie, J., Um, W., You, D. G., Kwon, S., Zhang, L., Zhu, J., & Park, J. H. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202008061 · Cited by 99
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 101
Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
Champiat, S., Ileana, E. E., Giaccone, G., Besse, B., Mountzios, G., Eggermont, A. M. M., & Soria, J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000074 · Cited by 96
Antigen specificity of immune suppression by myeloid-derived suppressor cells
Solito, S., Bronte, V., & Mandruzzato, S. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0111021 · Cited by 96
The growing diversity and spectrum of action of myeloid‐derived suppressor cells
Mantovani, A. (2010) · European Journal of Immunology · doi:10.1002/eji.201041170 · Cited by 95
Kanda, S., Goto, K., Shiraishi, H., Kubo, E., Tanaka, A., Utsumi, H., Sunami, K., Kitazono, S., Mizugaki, H., Horinouchi, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw416 · Cited by 94
Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation
Zheng, H., Siddharth, S., Parida, S., Wu, X., & Sharma, D. (2021) · Cancers · doi:10.3390/cancers13133357 · Cited by 95
Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3397 · Cited by 92
The immunobiology of myeloid-derived suppressor cells in cancer
Motallebnezhad, M., Jadidi‐Niaragh, F., Qamsari, E. S., Bagheri, S., Gharibi, T., & Yousefi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4477-9 · Cited by 95
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells
Nagaraj, S., & Gabrilovich, D. I. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.010 · Cited by 92
Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
Sun, B., Hyun, H., Li, L., & Wang, A. Z. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0424-4 · Cited by 91
Combining chemotherapy with CAR-T cell therapy in treating solid tumors
Wang, A. X., Ong, X., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140541 · Cited by 94
Sawant, A., & Ponnazhagan, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0305 · Cited by 92
Kongsted, P., Borch, T. H., Ellebæk, E., Iversen, T. Z., Andersen, R. S., Met, Ö., Hansen, M., Lindberg, H., Sengeløv, L., & Svane, I. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.01.007 · Cited by 89
Kersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 92
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
Gao, X., Sui, H., Zhao, S., Gao, X., Su, Y., & Qu, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585214 · Cited by 88
Myeloid-derived suppressor cells in transplantation and cancer
Ochando, J., & Chen, S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8335-1 · Cited by 86
ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Shurin, M. R., Naiditch, H., Gutkin, D. W., Umansky, V., & Shurin, G. V. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800099785 · Cited by 86
Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
Moghadam, E. R., Ang, H. L., Asnaf, S. E., Zabolian, A., Saleki, H., Yavari, M. D., Esmaeili, H., Zarrabi, A., Ashrafizadeh, M., & Kumar, A. P. (2020) · Biomolecules · doi:10.3390/biom10101374 · Cited by 87
Hecht, M., Gostian, A., Eckstein, M., Rutzner, S., von der Grün, J., Illmer, T., Hautmann, M., Klautke, G., Laban, S. A., Brunner, T. B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001378 · Cited by 84
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 83
Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Myeloid derived suppressor cells
Waldron, T. J., Quatromoni, J. G., Karakasheva, T. A., Singhal, S. K., & Rustgi, A. K. (2013) · OncoImmunology · doi:10.4161/onci.24117 · Cited by 81
Centuori, S. M., Trad, M., LaCasse, C. J., Alizadeh, D., Larmonier, C. B., Hanke, N. T., Kartchner, J., Janikashvili, N., Bonnotte, B., Larmonier, N., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0911465 · Cited by 80
Yu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 88
Dufait, I., Schwarze, J. K., Liechtenstein, T., Leonard, W., Jiang, H., Escors, D., Ridder, M. D., & Breckpot, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3682 · Cited by 81
Sheng, D., Ma, W., Zhang, R., Zhou, L., Deng, Q., Tu, J., Chen, W., Zhang, F., Gao, N., Dong, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003793 · Cited by 77
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Pandha, H., Simpson, G. R., Relph, K., Melcher, A. A., & Harrington, K. J. (2016) · Oncolytic Virotherapy · doi:10.2147/ov.s66083 · Cited by 77
Fumet, J.-D., Limagne, E., Thibaudin, M., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12092637 · Cited by 80
Advances in and prospects of immunotherapy for prostate cancer
Liu, D., Wang, L., & Guo, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217155 · Cited by 78
Rosborough, B. R., Castellaneta, A., Natarajan, S., Thomson, A. W., & Turnquist, H. R. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311119 · Cited by 75
Hutcheson, J., Balaji, U., Porembka, M. R., Wachsmann, M., McCue, P. A., Knudsen, E. S., & Witkiewicz, A. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1883 · Cited by 77
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
Nguyen, A., Ho, L., & Wan, Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00145 · Cited by 74
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 75
Akinsipe, T., Mohamedelhassan, R., Akinpelu, A., Pondugula, S. R., Mistriotis, P., Avila, L. A., & Suryawanshi, A. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1302587 · Cited by 80
Wang, H., Ning, F., Liu, Z., Wu, L., Li, Z.-Q., Qi, Y.-F., Zhang, G., Wang, H., Cai, S., & Du, J. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1935-1 · Cited by 72
Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
Zeng, A., Yu, Y., Yao, Y.-Q., Yang, F.-F., Liao, M., Song, L.-J., Li, Y.-L., Yu, Y., Li, Y., Zeng, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23376 · Cited by 73
He, W., Liang, P., Guo, G., Huang, Z. D., Niu, Y., Dong, L., Wang, C., & Zhang, J. (2016) · Scientific Reports · doi:10.1038/srep24506 · Cited by 70
Ye, T., Wei, X., Yin, T., Xia, Y., Li, D., Shao, B., Song, X., He, S., Luo, M., Gao, X., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2829-y · Cited by 70
Cancer-Associated Myeloid Regulatory Cells
Vlaeminck, Y. D., González-Rascón, A. A., Goyvaerts, C., & Breckpot, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00113 · Cited by 73
Pusuluri, A., Wu, D., & Mitragotri, S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.020 · Cited by 70
Chen, C.-S., Doloff, J. C., & Waxman, D. J. (2014) · Neoplasia · doi:10.1593/neo.131910 · Cited by 68
Ghansah, T., Vohra, N. A., Kinney, K., Weber, A. M., Kodumudi, K. N., Springett, G. M., Sarnaik, A. A., & Pilon‐Thomas, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1407-9 · Cited by 68
Self-citationZhang, L., Zhou, C., Zhang, S., Chen, X., Liu, J., Xu, F., & Liang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939249 · Cited by 68
Wang, J., Su, X., Liu, Y., Qiao, F., Yu, F., Yu, L., Yang, Q., Wang, Y., Yin, Y., Chen, R., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.29998 · Cited by 67
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
Belderbos, R. A., Aerts, J. G. J. V., & Vroman, H. H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.007 · Cited by 67
Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy
Li, Q., Liu, X., Yan, C., Zhao, B., Zhao, Y., Yang, L., Shi, M., Yu, H., Li, X., & Luo, K. (2023) · Small · doi:10.1002/smll.202206211 · Cited by 68
Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells
Zhang, Y., Yang, S., Yang, Y., & Liu, T. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0247-4 · Cited by 66
Rébé, C., & Ghiringhelli, F. (2015) · Future Oncology · doi:10.2217/fon.15.198 · Cited by 67
Current status of immunotherapy
Suzuki, S., Ishida, T., Yoshikawa, K., & Ueda, R. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv201 · Cited by 66
Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis
Ray, A., Hu, K. H., Kersten, K., Courau, T., Kuhn, N. F., Zaleta-Linares, I., Samad, B., Combes, A. J., & Krummel, M. F. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240957 · Cited by 68
Albeituni, S., Ding, C., & Yan, J. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000006 · Cited by 65
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
Wang, Y., Jia, A., Bi, Y., Wang, Y., Yang, Q., Cao, Y., Li, Y., & Liu, G. (2020) · Cancers · doi:10.3390/cancers12092626 · Cited by 64
Immunological off-target effects of standard treatments in gastrointestinal cancers
Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 63
Choi, H.-J., Choi, H., Chung, T., & Ha, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.002 · Cited by 63
Wang, Z., Liu, Y., Zhang, Y., Shang, Y., & Gao, Q. (2015) · Oncotarget · doi:10.18632/oncotarget.6734 · Cited by 63
Improving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C. C. H., Spilgies, L. M., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 63
Huang, X., Cui, S., & Shu, Y. (2015) · Immunologic Research · doi:10.1007/s12026-015-8734-1 · Cited by 64
Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle
Kim, K. S., Youn, Y. S., & Bae, Y. H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.027 · Cited by 63
Future prospects for mitosis-targeted antitumor therapies
del Valle, A. S., Reina-Ortiz, C., Benedi, A., Anel, A., Naval, J., & Marzo, I. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114655 · Cited by 62
Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis
Lo, C. H., & Lynch, C. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00247 · Cited by 61
Xu, P., Yin, K., Tang, X., Tian, J., Zhang, Y., Ma, J., Xu, H., Xu, Q., & Wang, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109458 · Cited by 61
Docetaxel promotes the generation of anti-tumorigenic human macrophages
Millrud, C. R., Mehmeti, M., & Leandersson, K. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.018 · Cited by 60
Lu, X., Ding, Z., Cao, Y., Liu, C., Habtetsion, T. G., Yu, M., Lemos, H. D. P., Salman, H., Xu, H., Mellor, A. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401894 · Cited by 61
Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity
Fujimura, T., Kakizaki, A., Furudate, S., Kambayashi, Y., & Aiba, S. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.05.015 · Cited by 59
Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy
Wang, X., Li, D., Li, G., Chen, J., Yang, Y., Bian, L., Zhou, J., Wu, Y., & Chen, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073645 · Cited by 61
Zheng, D., Wan, C., Yang, H., Xu, L., Dong, Q., Du, C., Du, J., & Li, F. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s271213 · Cited by 56
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments
Chan, T., Wiltrout, R. H., & Weiss, J. M. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.12.024 · Cited by 56
Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression
Sica, A., Guarneri, V., & Gennari, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.197 · Cited by 56
Targeting Myeloid-Derived Suppressor Cells in Cancer
Anani, W. Q., & Shurin, M. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_8 · Cited by 55
Zheng, H., Zeltsman, M., Zauderer, M. G., Eguchi, T., Vaghjiani, R. G., & Adusumilli, P. S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0052 · Cited by 56
Zheng, J., Huang, J., Zhang, L., Wang, M., Xu, L., Dou, X., Leng, X., Fang, M., Sun, Y., & Wang, Z. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00350-5 · Cited by 54
Fußer, M., Øverbye, A., Pandya, A. D., Mørch, Y. A., Borgos, S. E., Kildal, W., Snipstad, S., Sulheim, E., Fleten, K. G., Askautrud, H. A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.029 · Cited by 54
Khan, M. B., Du, K., Ai, M.-L., Wang, B., Lin, J., Ren, A., Chen, C., Huang, Z., Qiu, W., Yuan, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1060308 · Cited by 52
MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target
Liu, H., Wang, Z., Yuntao, Z., & Yang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199273 · Cited by 55
Liu, L., Ye, T., Han, Y., Song, H., Zhang, Y. K., Xia, Y., Wang, N., Xiong, Y., Song, X. J., Zhu, Y. X., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358640 · Cited by 52
Mace, T. A., King, S. A., Ameen, Z., Elnaggar, O., Young, G. S., Riedl, K. M., Schwartz, S. J., Clinton, S. K., Knobloch, T. J., Weghorst, C. M., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1564-5 · Cited by 51
Gallego‐Yerga, L., Lomazzi, M., Sansone, F., Mellet, C. O., Casnati, A., & Fernández, J. M. G. (2014) · Chemical Communications · doi:10.1039/c4cc02703e · Cited by 51
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 52
Han, Y., Tian, X., Zhai, J., & Zhang, Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1363121 · Cited by 51
Mikyšková, R., Indrová, M., Vlková, V., Bieblová, J., Šímová, J., Paračková, Z., Pajtasz‐Piasecka, E., Rossowska, J., & Reiniš, M. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.0813435 · Cited by 50
New insights into metronomic chemotherapy-induced immunoregulation
Hao, Y., Yi, S., Ruan, J., Zhao, L., & Nan, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.028 · Cited by 50
Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer
Mabuchi, S., Sasano, T., & Komura, N. (2021) · Cells · doi:10.3390/cells10020329 · Cited by 55
Wang, Y., Liu, H., Zhang, Z., Bian, D., Shao, K., Wang, S., & Ding, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006166 · Cited by 49
Drake, C. G., Sharma, P., & Gerritsen, W. R. (2013) · Oncogene · doi:10.1038/onc.2013.497 · Cited by 49
Accolla, R. S., Lombardo, L., Abdallah, R., Raval, G., Forlani, G., & Tosi, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00032 · Cited by 49
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Mitri, D. D., Toso, A., & Alimonti, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2261 · Cited by 50
Kim, H., Griffith, T. S., & Panyam, J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254953 · Cited by 49
Weigert, A., Mora, J., Sekar, D., Syed, S. N., & Brüne, B. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_9 · Cited by 48
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
Modica, M. D., Sfondrini, L., Regondi, V., Varchetta, S., Oliviero, B., Mariani, G., Bianchi, G., Generali, D., Balsari, A., Triulzi, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6353 · Cited by 47
Feola, S., Capasso, C., Fusciello, M., Martins, B., Tähtinen, S., Medeot, M., Carpi, S., Frascaro, F., Ylösmäki, E. O., Peltonen, K., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1457596 · Cited by 47
Zhu, Y.-J., Chang, X., Zhou, R., Chen, Y., Ma, H., Xiao, Z., Qu, X., Liu, Y., Liu, L., Li, Y., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.006 · Cited by 46
Dongsar, T. S., Dongsar, T. T., Molugulu, N., Annadurai, S., Wahab, S., Gupta, N., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116455 · Cited by 46
Tsutsumi, C., Ohuchida, K., Katayama, N., Yamada, Y., Nakamura, S., Okuda, S., Otsubo, Y., Iwamoto, C., Torata, N., Horioka, K., et al. (2024) · Gastric Cancer · doi:10.1007/s10120-023-01456-4 · Cited by 48
Paclitaxel nanoparticle awakens immune system to fight against cancer
Tang, W., Yang, J., Yuan, Y., Zhao, Z., Lian, Z., & Liang, G. (2017) · Nanoscale · doi:10.1039/c6nr09895a · Cited by 46
Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 46
Metadata
- Authors
- Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y.
- Affiliations
- Moffitt Cancer Center (US)
- Authors' Affiliation: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida
- Corresponding author
- Djeu, Julie Y.
- Venue
- Clinical Cancer Research
- Published
- 2010-09-14
- Volume
- 16
- Issue
- 18
- Pages
- 4583-4594
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3874864
- OpenAlex
- W2143994426
- Cited by
- 500
- References
- 42
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 33 · 2023: 32 · 2022: 37 · 2021: 39 · 2020: 39 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 42 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 22
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (T32CA115308)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- docetaxel, myeloid-derived suppressor cells, tumor immunosuppression, CTL response, CD4+ T cell activation, CD206, CCR7, macrophage differentiation, STAT3 signaling, tumor-bearing mice
- MeSH terms
- Docetaxel, Animals, Antineoplastic Agents, Cell Differentiation, Cytotoxicity, Immunologic, Female, Immune Tolerance, Immunosuppressive Agents, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Transplantation, Neoplasms, T-Lymphocytes, Myeloid Cells, Taxoids, Cell Line, Tumor, Mice, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
